Drug details

Padcev (enfortumab vedotin-ejfv for injection)

type of Antineoplastics, Antimicrotubular, Anti-Nectin-4 Monoclonal Antibodies

Padcev (enfortumab vedotin-ejfv) is a Nectin-4-directed antibody and microtubule inhibitor conjugate used to treat adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• nausea,
• loss of appetite,
• vomiting,
• confusion,
• stomach pain,
• dry mouth,
• increased thirst,
• increased urination,
• fruity breath odor,
• drowsiness,
• vision problems, and
• numbness, tingling, or burning pain in your hands or feet,
• pain, redness, and peeling skin on your or feet,
• severe skin rash with itching, scaling, or blisters,
• severely dry eyes,
• redness, itching, swelling, or discomfort where the medicine was injected

The following drugs are related to Padcev, either as a replacement or used together:

• Adstiladrin (nadofaragene firadenovec-vncg suspension, for intravesical use)
• Tecentriq (atezolizumab injection)
• Bavencio (avelumab injection)
• Balversa (erdafitinib tablets)
• Cisplatin (cisplatin injection)
• Imfinzi (durvalumab injection)
• Jelmyto (mitomycin for pyelocalyceal solution)
• Keytruda (pembrolizumab for injection)
• Opdivo (nivolumab injection)
• Thiotepa (thiotepa injection)
• Valstar (valrubicin)
• Vinblastine Sulfate (vinblastine sulfate injection)